COLORECTAL HEALTH ALERT: Opdivo Approved for MSI-High Colorectal Cancer Patients

Bristol-Meyers Squibb’s Opdivo (nivolumab) has just been approved by the FDA for patients with a microsatellite instability-high tumors (also known as MSI-H) or mismatched repair deficiency (dMMR). The approval was specifically for patients whose cancer has progressed following Fluoropyrimidine, Oxaliplatin, and Irinotecan.

Opdivo joins Merck’s Keytruda (pembrolizumab) as the second immunotherapy drug to be approved within four months. Here’s what you need to know.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s